Sector Expert: Sandesh Seth

Actinium Pharmaceuticals Inc.

Sandesh Seth is the executive chairman of Actinium Pharmaceuticals Inc., a biopharmaceutical company developing innovative, targeted payload radioimmunotherapeutics for the treatment of advanced cancers. Mr. Seth has 20-plus years of healthcare industry experience that encompasses in investment banking (Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and the pharma industry (Pfizer, Warner-Lambert, SmithKline in strategic planning, business development and R&D project management). In addition, Mr. Seth is the chairman of Relmada Therapeutics Inc., a publicly listed specialty pharmaceuticals company focused on pain therapeutics. He has an M.S. in pharmaceutical science from the University of Oklahoma, and an M.B.A. in finance from New York University's Leonard Stern School of Business.



Recent Interviews

Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs (8/17/16)
ActiniumImage630

Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. is in position to benefit, according to company executive chairman Sandesh Seth. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching.



Due to permission requirements, not all quotes are shown.